The Phase 3 clinical trial for Retatrutide (NCT05882045) in participants with obesity and cardiovascular disease reached its primary completion on April 30, 2026. This study, which enrolled 1800 participants, aims to evaluate the efficacy and safety of once-weekly retatrutide.
Background
Obesity and cardiovascular diseases (CVD) are significant global health challenges. Obesity is a major risk factor for the development and progression of various CVDs, including coronary artery disease, heart failure, and stroke. Managing these co-occurring conditions is crucial for improving patient outcomes and reducing the burden on healthcare systems.
Trial design
This Phase 3 study (NCT05882045) is investigating Retatrutide in participants with Obesity and established Cardiovascular Disease. The trial has an estimated enrollment of 1800 participants and is designed to evaluate the efficacy and safety of once-weekly retatrutide compared to placebo. The study duration is approximately 113 weeks.
What this means
The primary completion of this Phase 3 trial for Retatrutide signifies a key milestone in its development for treating obesity and cardiovascular disease. While specific efficacy and safety results are not yet available, the completion of this phase indicates that the primary data collection period has concluded. Clinicians, researchers, and patient advocates will await the detailed findings from this large-scale study, which are expected to provide crucial insights into retatrutide's potential role in managing these complex conditions.
Source
Information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The study record for NCT05882045, titled 'A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease,' was updated to reflect primary completion on April 30, 2026, on clinicaltrials.gov.